Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
| Autor: | Aron Goldhirsch, Hervé Bonnefoi, Lucien Perey, Jürg Bernhard, Monica Castiglione, Beat Thürlimann, Marisa Bacchi, C. Hürny, Marzio E E Sabbioni, Hans Peter Siegrist, Hans-Jörg Senn |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Cellular immunity Antineoplastic Agents Hormonal Cyclophosphamide Lymphocyte B-Lymphocyte Subsets Breast Neoplasms Breast cancer stomatognathic system T-Lymphocyte Subsets Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Adjuvant therapy Humans Cytotoxic T cell Drug Interactions skin and connective tissue diseases Aged business.industry Middle Aged Flow Cytometry Antiestrogen medicine.disease Combined Modality Therapy Tamoxifen Methotrexate medicine.anatomical_structure Chemotherapy Adjuvant Immunology Female Fluorouracil Cisplatin business hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Supportive Care in Cancer. 7:149-153 |
| ISSN: | 1433-7339 0941-4355 |
| DOI: | 10.1007/s005200050245 |
| Popis: | The effects and interaction of endocrine and cytotoxic adjuvant treatment on measures of cellular immunity were assessed in 41 stage I-II breast cancer patients from International Breast Cancer Study Group trials. Counts of lymphocytes and lymphocyte subsets [(T, T4, T8, B, natural killer (NK) and activated T (AT) cells] were assessed by flow cytometry immediately before adjuvant therapy at baseline and on day 1 of the 3rd cycle. Twenty-two patients received cyclophosphamide, methotrexate and 5-fluorouracil (CMF), 7 CMF and tamoxifen (TAM), and 12 TAM alone. On day 1 of the 3rd cycle the counts of total lymphocytes (P = 0.003) and all lymphocyte subsets (P0.05) except AT cells were significantly lower than baseline in the CMF treatment group. There was no significant change in the CMF+TAM or in the TAM treatment group. The combination of CMF and TAM resulted in less pronounced decrease in lymphocyte and subset counts from baseline to day 1 of the 3rd cycle. It seems possible that there is an interaction between TAM with CMF that affects lymphocyte and lymphocyte subset counts during cytotoxic treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink